4.8 Article

Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells

Journal

NATURE BIOTECHNOLOGY
Volume 37, Issue 12, Pages 1493-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41587-019-0235-7

Keywords

-

Funding

  1. Locus Biosciences
  2. Allen Distinguished Investigator Award from the Paul G. Allen Frontiers Group
  3. Thorek Memorial Foundation
  4. US National Institutes of Health (NIH) [R01DA036865]
  5. NIH Director's New Innovator Award [DP2OD008586]
  6. US National Science Foundation (NSF) Faculty Early Career Development (CAREER) Award [CBET-1151035]
  7. NSF [DMR-1709527]
  8. NSF Emerging Frontiers in Research and Innovation (EFRI) Award [EFMA-1830957]
  9. Pfizer-NCBiotech Distinguished Postdoctoral Fellowship
  10. NIH [T32GM008555, F31NS105419]
  11. NC State University
  12. NIH Maximizing Investigator's Research Award [1R35GM119561-01]

Ask authors/readers for more resources

Class 2 CRISPR-Cas systems, such as Cas9 and Cas12, have been widely used to target DNA sequences in eukaryotic genomes. However, class 1 CRISPR-Cas systems, which represent about 90% of all CRISPR systems in nature, remain largely unexplored for genome engineering applications. Here, we show that class 1 CRISPR-Cas systems can be expressed in mammalian cells and used for DNA targeting and transcriptional control. We repurpose type I variants of class 1 CRISPR-Cas systems from Escherichia coli and Listeria monocytogenes, which target DNA via a multi-component RNA-guided complex termed Cascade. We validate Cascade expression, complex formation and nuclear localization in human cells, and demonstrate programmable CRISPR RNA (crRNA)-mediated targeting of specific loci in the human genome. By tethering activation and repression domains to Cascade, we modulate the expression of targeted endogenous genes in human cells. This study demonstrates the use of Cascade as a CRISPR-based technology for targeted eukaryotic gene regulation, highlighting class 1 CRISPR-Cas systems for further exploration.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available